These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 23074235)

  • 1. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
    Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model.
    Luconi M; Mangoni M; Gelmini S; Poli G; Nesi G; Francalanci M; Pratesi N; Cantini G; Lombardi A; Pepi M; Ercolino T; Serio M; Orlando C; Mannelli M
    Endocr Relat Cancer; 2010 Mar; 17(1):169-77. PubMed ID: 19955217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The estrogen receptor (ER)alpha variant Delta5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells.
    Bryant W; Snowhite AE; Rice LW; Shupnik MA
    Endocrinology; 2005 Feb; 146(2):751-9. PubMed ID: 15528307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
    Hwang KA; Park MA; Kang NH; Yi BR; Hyun SH; Jeung EB; Choi KC
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):637-46. PubMed ID: 23933164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiestrogens upregulate estrogen receptor beta expression and inhibit adrenocortical H295R cell proliferation.
    Montanaro D; Maggiolini M; Recchia AG; Sirianni R; Aquila S; Barzon L; Fallo F; Andò S; Pezzi V
    J Mol Endocrinol; 2005 Oct; 35(2):245-56. PubMed ID: 16216906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer.
    Chan KK; Leung TH; Chan DW; Wei N; Lau GT; Liu SS; Siu MK; Ngan HY
    J Endocrinol; 2014 May; 221(2):325-36. PubMed ID: 24819599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
    Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
    J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line.
    Eertmans F; Dhooge W; De Wever O; Bracke M; Comhaire F; Kaufman JM
    J Cell Physiol; 2007 Sep; 212(3):583-90. PubMed ID: 17458895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner.
    Hermani A; Shukla A; Medunjanin S; Werner H; Mayer D
    Cell Signal; 2013 Jun; 25(6):1395-402. PubMed ID: 23499909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Scaffold Protein Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) in the Modulation of Adrenocortical Cancer Cell Growth.
    De Luca A; Avena P; Sirianni R; Chimento A; Fallo F; Pilon C; Casaburi I; Pezzi V
    Cells; 2017 Nov; 6(4):. PubMed ID: 29112114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation.
    Sirianni R; Chimento A; Malivindi R; Mazzitelli I; Andò S; Pezzi V
    Cancer Res; 2007 Sep; 67(17):8368-77. PubMed ID: 17804753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.
    Secreto FJ; Monroe DG; Dutta S; Ingle JN; Spelsberg TC
    J Cell Biochem; 2007 Aug; 101(5):1125-47. PubMed ID: 17520659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.
    Chimento A; Sirianni R; Casaburi I; Zolea F; Rizza P; Avena P; Malivindi R; De Luca A; Campana C; Martire E; Domanico F; Fallo F; Carpinelli G; Cerquetti L; Amendola D; Stigliano A; Pezzi V
    Oncotarget; 2015 Aug; 6(22):19190-203. PubMed ID: 26131713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.